FAP and cancer: A preclinical study using the KPC mouse model suggested that depletion of fibroblast-associated protein (FAP)-positive cancer-associated fibroblasts (CAFs) sensitized the tumor to the treatment with anti-PD-L1 monoclonal antibody [107].